"Rick is a 25-year veteran of regulatory affairs and brings a long track record of success to our team"
Perseon Corporation (NASDAQ:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced the appointment of Rick Gaykowski as Vice President of Regulatory, Quality & Clinical Affairs effective May 1, 2015.
Top Company Interviews
"Rick is a 25-year veteran of regulatory affairs and brings a long track record of success to our team," said Clint Carnell, CEO of Perseon. "His high caliber of expertise and extensive relationships will be invaluable to Perseon as we continue to enhance our evidence-based approach and expand our speed of innovation within the high-growth energy ablation market."
Over his 25-year career, Mr. Gaykowski has held various management and leadership positions within the medical device and healthcare industries. Most recently he was Global Vice President, Regulatory Affairs & Quality Systems for Nasdaq-listed Lumenis, one of the world's leading manufacturers of medical laser equipment. Before joining Lumenis in 2010, Mr. Gaykowski served as Vice President, Regulatory Affairs for Bard Access Systems, Inc., and earlier, he held various leadership positions in regulatory affairs and quality assurance at Boston Scientific, InnerDyne, Inc., CardioPulmonics, Inc., and Symbion, Inc. Mr. Gaykowski holds a Bachelor's Degree in Behavioral Sciences and Health from the University of Utah.
Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
# # #
This content was issued by BSD Medical Corporation on the 2015-05-07 and was initially posted on www.bsdmedical.com. It was distributed, unedited and unaltered, by noodls on 2015-05-09 01:28:23 UTC. The original issuer is solely responsible for the accuracy of the information contained therein.
Top Company Interviews
Register for a Free Account to gain greater access to
The Wall Street Transcript right now